NDAORALTABLET
Approved
Mar 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEEBACIN (aminosalicylate sodium) is an oral tablet antibiotic approved in 1950 for the treatment of tuberculosis. It functions as a bacteriostatic agent used in combination therapy regimens. The drug is indicated for patients with tuberculosis, particularly those with drug-resistant or difficult-to-treat infections.
LOE Approaching
Moderate competitive pressure (30/100) with only 4 linked jobs suggests a mature, stable product with limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With only 4 linked jobs concentrated in director-level and head positions within Medical Affairs and Clinical Development, opportunities are limited to senior, strategic roles. This product profile suggests stable maintenance of a legacy asset rather than growth-oriented expansion, making it suitable for experienced professionals managing mature portfolios.
Directoror Executive Medical Director
Worked on TEEBACIN at Century Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.